Guizhou Sanli Pharmaceutical Co.,Ltd. (603439.SH): There is currently no layout in the field of AI medicine.

On February 18, Gelonghui reported that Guizhou Sanli Pharmaceutical Co.,Ltd. stated on the interactive platform that the company currently has no layout in the field of AI medicine.

Gelonghui FinanceFeb 18 15:49

Guizhou Sanli Pharmaceutical Co.,Ltd. (603439.SH): The company did not implement share buybacks in December.

Gelonghui reported on January 2 that Guizhou Sanli Pharmaceutical Co.,Ltd. (603439.SH) announced that from December 1, 2024, to December 31, 2024, the company did not implement any share buybacks. As of December 31, 2024, the company has cumulatively repurchased 7,869,300 shares through centralized bidding, accounting for 1.92% of the company's total share capital as of the date of this announcement. The maximum repurchase price was 14.20 yuan per share, the minimum repurchase price was 11.82 yuan per share, and the total amount paid was 99,954,426.00 yuan (excluding transaction fees).

Gelonghui FinanceJan 2 15:39

Guizhou Sanli Pharmaceutical Co.,Ltd. (603439.SH): plans to jointly invest with professional investment institutions to establish a venture capital fund.

On December 26, the company Guizhou Sanli Pharmaceutical Co., Ltd. (603439.SH) announced that it has recently signed a partnership agreement for the Guizhou Qianli Biomedical Venture Capital Fund Limited Partnership with its holding subsidiary Yunnan Wudi, Guizhou Zhuyin Capital Management Co., Ltd., Guiyang Industrial Development Fund Partnership (Limited Partnership), Guiyang Venture Capital Co., Ltd., and Guizhou Wudang Economic Development Zone Construction Investment Development Co., Ltd. The Fund plans to focus on investing in industries related to Biomedical, including but not limited to Biotechnology, pharmaceutical manufacturing, medical instruments, and Medical Services.

Gelonghui FinanceDec 26, 2024 17:45

HAITONG SEC: The trend of moderate price reductions in the centralized procurement of Traditional Chinese Medicine varieties continues, and the domestic Pharmaceutical industry is expected to usher in a wave of mergers and acquisitions.

HAITONG SEC released a Research Report stating that the gentle trend of price reduction for Traditional Chinese Medicine varieties continues.

Zhitong FinanceDec 13, 2024 07:20

Guizhou Sanli Pharmaceutical Co., Ltd. (603439.SH): plans to acquire 22.9111% equity in Hanfang Pharmaceutical.

On December 3, Glonghui reported that guizhou sanli pharmaceutical co.,ltd. (603439.SH) announced that the company plans to acquire 22.9111% of the equity held by Mr. Deng Daixing in guizhou hanfang pharmaceutical co., ltd. (referred to as "hanfang pharmaceutical"). The price for this equity transfer is RMB 169.83 million, to be paid in cash. Prior to this equity transfer, hanfang pharmaceutical is a subsidiary controlled by the company, which holds 75.8928% of its equity; after the completion of this equity transfer, the company will hold 98.8039% of hanfang pharmaceutical's equity.

Gelonghui FinanceDec 3, 2024 17:32

guizhou sanli pharmaceutical co.,ltd. (603439.SH): There are no products related to snakes among the products currently in production and for sale at guizhou sanli pharmaceutical co.,ltd.

On November 26, Gelonhui reported that guizhou sanli pharmaceutical co.,ltd. (603439.SH) stated on the interactive platform that currently there are no products related to snakes among the products produced and sold by guizhou sanli pharmaceutical co.,ltd. However, subsidiaries guizhou hanfang pharmaceutical, guizhou dechangxiang, and yunnan wudi pharmaceutical have products with snake-related raw materials in their formulations.

Gelonghui FinanceNov 26, 2024 16:17